External-Examination-in-Chemistry1
Bringing Pharmaceutical solutions to the Hemp and Cannabis industry

ENHANCING EXISTING PHARMACEUTICAL PRODUCTS WITH PLANT DERIVED CANNABINOIDS THROUGH RESEARCH AND DEVELOPMENT

External-Examination-in-Chemistry1
ADVANCED PHARMACEUTICAL FORMULATIONS FOR THE TRADITIONAL SYMPTOMS

Research And Development Conducted Inhouse For Incorporating Cannabinoids Into A Number of Products

External-Examination-in-Chemistry1
Cannabinoids Have Been Linked To Multiple Therapeutic Indications

Pain Management . Sleep . Gastro-Intestinal . Mood/Behavious . Neurological

previous arrow
next arrow
null

Experience

Our team of highly experienced professionals have been active in various sectors of the health industry for many years giving the company the right direction and speed for progress.

null

Formulations and Genetics

By choosing specific target treatment areas with the combination of the right plant genetics and formulations XynaRx Pharmaceuticals is on the forefront of advanced medicine.

null

Facilities

Through setting up pharmaceutical and medical facilities around the world our team has the necessary tools and the aim to build one of the most advanced laboratories in Canada to be the reference in the Pharmaceutical market.

XynaRx Pharmaceuticals Corp.

XynaRx has established a position in the enhancement of existing pharmaceutical products with plant-derived cannabinoids through research and development processes, formulation expertise and manufacturing know-how. Research and development will be conducted in-house for incorporating Cannabinoids into number of Products. The company has focused on the following 5 major categories:

Milestones

BUILDING A STATE-OF-THE-ART PRODUCTION FACILITY
WELL SEASONED PHARMACEUTICAL PROFESSIONALS
TARGETING A $300+B AND GROWING MARKET
APPLYING FOR APPROVAL FOR NPN
(NATURAL PRODUCT NUMBER)
AND DIN (DRUG IDENTIFICATION NUMBER)

null

Target Market

Targeting a $300+B and growing market

null

Natural Product Number

Applying for approval for NPN
null

Drug Identification Number

Obtaining DIN numbers

Formulations

LIST OF SOME OF THE PHARMACEUTICAL FORMULATIONS IN OUR DATABASE

ACETAMINOPHEN 100 ORAL DROP

ACETAMINOPHEN 325 SCORED TABLETS

ACETAMINOPHEN 500 TABLET

IBUPROFEN 400 MG F.C TABLET

IBUPROFEN 200 MG F.C TABLET

PANTOPRAZOLE 40 MG TABLET

CALCIUM D3 250 MG/ 300 IU TABLETS

MELATONIN 3 MG SCORED TABLET

VITAMIN D3/1000 SOFT GEL CAPSULE

VITAMIN D3/1000 IU F.C (FILM-COATED) TABLETS

CALCIUM PLUS TABLET

VITAMIN A+ D3+ ZN+ FE ORAL DROP

VITAMIN E 400 SOFT GEL CAPSULE

MULTIVITAMIN PLUS MINERAL CAPSULES

FERROUS SULPHATE SRI/ FOLIC ACID/ ZINC SULPHATE 150/0.5/20

MEET OUR TEAM

DR. KAMRAN OMANIAN

Chief Executive Officer

Over 27 years in the telecommunications, oil and gas, and pharmaceutical industries. Previous general manager of Nikma Pharmaceutical Company, a firm active in importing and producing supplements. Taught strategic management and pharmaceutical marketing at Tehran University of Medical Sciences and Shahid Beheshti University.

ALLAN TAVAKOLI

Chief Financial Officer

A seasoned Chartered Professional Accountant with over 25 years of experience in finance both in public and private sectors. Mr. Tavakoli has helped facilitate many sales and acquisition deals (-100M+) involving retail high-tech, telecommunication as well as wholesale industries. In the past, he has held Director of Finance, Corporate Controller and Senior Accounting positions in Pharmaceuticals, telecommunications, BC Government and Mining industries.

MATTHEW K. WEBER

Director

President of The Concosts Group, Mr. Weber is responsible for the management of an umbrella of companies employing in excess of 50 full-time staff members. He is involved with over 47 real estate projects to date (total construction value ~$500 million), including concrete condominium mid/high-rise developments, steel-framed condominium developments,

DR. MIGUEL GALLACH

Director

15+ years experience in genomic research projects and next generation sequencing technologies. PhD at the University of Valencia, Spain, under the Molecular and Evolutionary Genetics and expertise in data science, experimental design, and applications of statistical and Machine Learning methods.

PROF. DR. ROBERT GORTER

Chief Medical Advisor

Prof. Dr. Robert Gorter was born and raised in the Netherlands and graduated at the University of Amsterdam in 1971. He specialized in Family and Community Medicine, Internal Medicine, Biostatistics, Addiction Medicine, Tropical Medicine and Oncology (University of Basel, Switzerland). From 1995 on, Dr. Gorter has been advising the German authorities (BfARM), Indian and the Dutch authorities in regard to licensing Cannabis sativa and its cannabinoids for medical use. Over the previous years and on multiple requests from patients around the world, Dr. Gorter has consented to hold on-line consultations for patients needing to know more about Cannabis and if Cannabis would be indicated for their health problems and disease; and prescribe it legally in many countries. Also, for the Dutch, German and Indian medical authorities, Dr. Gorter started a formal Continuous Medical Education (CME) program for doctors on the medical use of Cannabis.

TIMELINE

Q1 of 2022

XynaRx management established and acquired a number of pharmaceutical formulations (CTDs)

Q1 of 2022

Management anticipates the financing to be completed

Q3 of 2022

The facilities and laboratories of XynaRx will commence construction

Q4 of 2022

Company is expected to have submitted 3 Documents for NPN application to Health Canada

Q1 of 2023

Facility completion expected by the end of Q1

Q2 of 2023

Commencing laboratory work on 3 pharmaceutical formulations

Contact us

Call us for more information on our project or to explore investment opportunities.

1-604-351-1466

FOR INVESTMENT OPPORTUNITIES

info@XynaRx.com

CORPORATE HEADQUARTERS

Suit 112 – 828 Harbourside Dr. North Vancouver, BC, V7P 3R9

Contact With The Form

Fill out this field
Fill out this field
Fill out this field
Please enter a valid email address.
Fill out this field
Menu